GlassScriptPhysician profile
Harold W Cox
NPI 1114991072
$12,270.28
in general payments reported to CMS, 2019-2025
69 companies · $1,785 in 2025
The $1,785 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $842 · 2020: $1,572 · 2021: $2,574 · 2022: $2,288 · 2023: $1,639 · 2024: $1,570 · 2025: $1,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,900 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,900.49 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,238.09 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $994.00 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $815.79 | 2019-2025 | |
| Amgen INC. | $709.85 | 2019-2025 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $696.19 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $672.68 | 2019-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $489.89 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $451.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $407.31 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $392.71 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $358.08 | 2019-2025 | Xifaxan, Cycloset |
| Sumitomo Pharma America, INC. | $341.58 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $338.62 | 2019-2025 | |
| Esperion Therapeutics, INC. | $263.07 | 2020-2025 | Nexletol |
| Amarin Pharma, INC. | $246.25 | 2019-2022 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.